Zurueck zur Suche

Reporte zur Charge 7434N

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

3Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
WI 2 VA 1

VAERS 1004680

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 7434N

mild
Staat
VA
Alter
-
Geschlecht
M
Eingang
05.02.2021
Impfdatum
04.09.2020
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Pruritus Urticaria

Symptomtext

itching; hives; This case was reported by a pharmacist and described the occurrence of pruritus in a male patient who received Herpes zoster (Shingrix) (batch number 7434N, expiry date 24th April 2022) for prophylaxis. On 4th September 2020, the patient received Shingrix (intramuscular). On an unknown date, less than 2 weeks after receiving Shingrix, the patient experienced pruritus and hives. On an unknown date, the outcome of the pruritus and hives were recovered/resolved. It was unknown if the reporter considered the pruritus and hives to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported. The batch number was updated from 74342 to 7434N, as per sales data sheet. The patient experienced event and it could be on same day or a week after was not sure. The patient did not had hives or itching any more. The reporter did not consent to follow up. The reporter did not want to prove further details and did not agree to follow up and was not happy providing details. The reporter did not want to provide address and no further information provided.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pruritus
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1215702

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 7434N

gering
Staat
WI
Alter
55,0
Geschlecht
F
Eingang
15.04.2021
Impfdatum
30.10.2020
Beginn
30.10.2020
Tage bis Beginn
0,0
Dosis
1
Route/Site
SC / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect route of product administration

Symptomtext

received Shingrix second dose SC instead of IM; Shingrix first dose was given SC too; This case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number 7434N, expiry date 24th April 2022) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) (batch number 7434N, expiry date 24th April 2022) for prophylaxis. On 30th October 2020, the patient received the 1st dose of Shingrix (subcutaneous). On 1st April 2021, the patient received the 2nd dose of Shingrix (subcutaneous). On 30th October 2020, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On 1st April 2021, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route and intramuscular formulation administered by other route were unknown. Additional details were provided as follows: This case was reported by nurse on behalf of patient. The patient said to nurse that Shingrix 1st dose was given subcutaneously, which led to intramuscular formulation administered by other route, so the nurse gives 2nd dose of Shingrix at an ambulatory clinic, subcutaneously instead of intramuscularly, which led to intramuscular formulation administered by other route. The nurse was looking for safety information for this situation and stated that she needed to follow up with patient. The reporter consented to follow up at her private cellphone.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1215702

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge 7434N

gering
Staat
WI
Alter
55,0
Geschlecht
F
Eingang
15.04.2021
Impfdatum
30.10.2020
Beginn
30.10.2020
Tage bis Beginn
0,0
Dosis
2
Route/Site
SC / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect route of product administration

Symptomtext

received Shingrix second dose SC instead of IM; Shingrix first dose was given SC too; This case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number 7434N, expiry date 24th April 2022) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) (batch number 7434N, expiry date 24th April 2022) for prophylaxis. On 30th October 2020, the patient received the 1st dose of Shingrix (subcutaneous). On 1st April 2021, the patient received the 2nd dose of Shingrix (subcutaneous). On 30th October 2020, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On 1st April 2021, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route and intramuscular formulation administered by other route were unknown. Additional details were provided as follows: This case was reported by nurse on behalf of patient. The patient said to nurse that Shingrix 1st dose was given subcutaneously, which led to intramuscular formulation administered by other route, so the nurse gives 2nd dose of Shingrix at an ambulatory clinic, subcutaneously instead of intramuscularly, which led to intramuscular formulation administered by other route. The nurse was looking for safety information for this situation and stated that she needed to follow up with patient. The reporter consented to follow up at her private cellphone.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-